Home » Stocks » Allakos

Allakos Inc. (ALLK)

Stock Price: $91.06 USD 1.22 (1.36%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
After-hours: $95.05 +3.99 (4.38%) Oct 26, 6:52 PM

Stock Price Chart

Key Info

Market Cap 4.45B
Revenue (ttm) n/a
Net Income (ttm) -113.46M
Shares Out 48.91M
EPS (ttm) -2.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $91.06
Previous Close $89.84
Change ($) 1.22
Change (%) 1.36%
Day's Open 89.63
Day's Range 88.34 - 94.38
Day's Volume 149,619
52-Week Range 41.61 - 139.99

More Stats

Market Cap 4.45B
Enterprise Value 4.00B
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 48.91M
Float 25.15M
EPS (basic) -2.35
EPS (diluted) -2.36
FCF / Share -1.62
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.35M
Short Ratio 36.54
Short % of Float 25.26%
Beta 1.06
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 9.45
Revenue n/a
Operating Income -120.71M
Net Income -113.46M
Free Cash Flow -79.22M
Net Cash 454.95M
Net Cash / Share 9.30
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -23.42%
ROE -37.87%
ROIC -36.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 2

Analyst Consensus: Overweight

Price Target

(-8.19% downside)
Current: $91.06
Target: 83.60
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-91.42-45.72-22.25-17.06
Net Income-85.37-43.54-23.55-17.10
Shares Outstanding45.1919.831.621.31
Earnings Per Share-1.89-2.20-14.54-13.03
Operating Cash Flow-63.01-38.45-22.57-17.58
Capital Expenditures-0.77-6.95-0.26-0.23
Free Cash Flow-63.78-45.40-22.83-17.81
Cash & Equivalents49617985.2113.42
Total Debt---4.99
Net Cash / Debt49617985.218.43
Book Value496184-58.77-36.44
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Allakos Inc.
Country United States
Employees 103
CEO Robert Alexander

Stock Information

Ticker Symbol ALLK
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALLK
IPO Date July 19, 2018


Allakos operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.